RA - AnaptysBio initiated Outperform at TD Cowen on anti-inflammatory agents

2023-05-18 10:18:35 ET

TD Cowen launched its coverage on the clinical-stage biotech AnaptysBio ( NASDAQ: ANAB ) with an Outperform rating on Thursday, projecting its anti-inflammatory candidates rosnilimab and ANB032 to generate $1.5B in peak U.S. sales.

Rosnilimab, AnaptysBio’s ( ANAB ) lead asset, is in development for moderate-to-severe rheumatoid arthritis (RA), and a Phase 3 trial for the candidate is scheduled to start in Q3 2023 with topline data expected in mid-2025.

A monoclonal antibody designed to treat atopic dermatitis  (AD), ANB032, is currently undergoing a Phase 2 trial, with data expected by the end of next year.

“Our KOLs see room for differentiated assets in RA and AD, and we project ~$1.5B in peak sales for each indication should the therapies be successfully developed,” the analyst Joseph Thome argued.

The analyst also highlighted AnaptysBio’s ( ANAB ) therapeutic focus, noting that its immune cell-modulating antibodies have the potential to outperform the standard of care.

As reasons for the conclusion, the analyst points out that these agents indicate a broader mechanism of action than rival monoclonal antibody therapies and a differentiated safety profile compared to JAK inhibitors.

More on AnaptysBio

• AnaptysBio misses Street forecasts with its Q1 2023 financials
• AnaptysBio: Upside Could Be Lying Ahead Very Nicely

For further details see: